Related Experiment Video
Updated: May 11, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Effect of kurarinol on peripheral blood CTL surface PD-1 expression of patients with chronic hepatitis B]
Yin-Fang Zhu1, Xi-Bing Gu, Xiao-Juan Yang
1Wuxi Hospital for Infectious Diseases, China.
Insights
Kurarinol treatment reduced PD-1 expression on HBV-specific cytotoxic T lymphocytes (CTLs) in chronic hepatitis B patients. This enhanced CTL activity may contribute to inhibiting or clearing the hepatitis B virus (HBV).
Area of Science:
- Immunology
- Virology
- Pharmacology
Context:
- Chronic hepatitis B (CHB) is a significant global health concern.
- Immune evasion by the hepatitis B virus (HBV) poses challenges for treatment.
- Cytotoxic T lymphocytes (CTLs) play a crucial role in controlling HBV infection.
Purpose:
- To investigate the anti-viral mechanism of kurarinol in CHB patients.
- To assess the effect of kurarinol on programmed death-1 (PD-1) expression on CTLs.
- To evaluate kurarinol's impact on HBV-specific CTL levels and viral markers.
Summary:
- Kurarinol treatment in CHB patients led to a significant decrease in PD-1 expression on HBV-specific CTLs compared to baseline and the control group.
- The treatment group showed a significant increase in HBV-specific CTL levels post-treatment.
- Kurarinol administration resulted in higher rates of HBV DNA and HBeAg negativity compared to the control group.
Impact:
- Kurarinol demonstrates potential as an immunomodulatory agent for CHB treatment.
- Down-regulation of PD-1 expression by kurarinol enhances anti-HBV CTL responses.
- This study provides insights into a potential therapeutic mechanism for kurarinol in managing CHB.
Objective:
To explore the anti-viral mechanism of kurarinol through studying its influence on cytotoxic T lymphocyte (CTL) surface program death receptor-1 (PD-1) expression of patients with chronic hepatitis B (CHB).
Methods:
69 cases of CHB, HBV DNA > or = 10(4) copies/ml, HBeAg positive, human leukocyte antigen (HLA)-A2 positive, alanine aminotransferase (ALT) > 2 x upper limit of normal value(ULN).69 cases were randomly divided into two groups:34 cases in treatment group,600 mg of kurarinol glucose injection was used for intravenous dripping, once a day, one month later, 200 mg of kurarinol capsule was used orally,three times a day and 200 mg of silybin meglumine tablet was used orally, three times a day. 35 cases in control group, only silibin meglumine tablet was used, method and dosage were the same as those of treatment group. Three months later, their peripheral blood HBV specific CTL surface PD-1 expression, non-specific CTL surface PD-1 expression and level of HBV specific CTL,HBV DNA and HBeAg negative rate and liver functions were analyzed and compared.
Results:
3 months after treatment, peripheral blood HBV specific CTL surface PD-1 expression of the treatment group decreased compared with that before treatment (t = 2.39, P < 0.05), it also decreased compared with that of the control group 3 months after treatment (t = 2.26, P < 0.05), HBV specific CTL increased compared with that before treatment( t = 3.01, P < 0.01), it also increased compared with that of the control group after treatment (t = 2.65, P < 0.05). There was no significant difference of non-specific CTL surface PD-1 expression compared with that before treatment (P > 0.05), and there was no significant difference compared with that of the control group after treatment (P > 0.05). HBV DNA of 11 cases (32.5%) turned negative ( HBV DNA < 500 copies/ ml), higher than that of the control group after treatment (2 cases, 5.71%) chi2 = 7.99, P < 0.01, HBeAg of 9 cases (26.47%) turned negative, higher than that of the control group after treatment (1 case, 2.86%), chi2 = 7.75, P < 0.01.
Conclusion:
Kurarinol can increase level of HBV specific CTL by down-regulating peripheral blood HBV specific CTL surface PD-1 expression of CHB patients, which may be one of the possible mechanisms that kurarinol can remove or inhibit HBV of CHB patients.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:25Hepatitis